第711期

本篇報告導(dǎo)讀

A key debate that has contributed to the underperformance of CSL, Grifols and Takeda, the global plasma fractionators, has been the impact of a potential new class of drugs (FcRn) on sales of immunoglobulin (Ig) in the second-biggest disease where Ig is used, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).?

CIDP is a rare condition with up to 40ktreated patients, but which accounts for some US$3bn out of US$12.8bn of global Ig sales.Leveraging the expertise of our global team, and based on a proprietary survey of 50 US neurologists, in this Global Connections Series report we review this debate and conclude that the market maybe too pessimistic on the plasma companies.

關(guān)于我們

全行業(yè)報告圈是一家專注于分享國內(nèi)外各類行業(yè)研究報告/專題熱點(diǎn)行業(yè)報告/白皮書/藍(lán)皮書/年度報告等各類優(yōu)質(zhì)研究報告分享平臺。所有報告來源于國內(nèi)外數(shù)百家機(jī)構(gòu)，包含零售消費(fèi)、金融領(lǐng)域、互聯(lián)網(wǎng)+、機(jī)械制造、新能源產(chǎn)業(yè)等專題研究.....目前已累積收集近40000+份行業(yè)報告，涉及11大板塊，305個細(xì)分領(lǐng)域

免責(zé)聲明

本平臺只做內(nèi)容的收集及分享，報告版權(quán)歸原撰寫發(fā)布機(jī)構(gòu)所有，由全行業(yè)報告圈社群朋友通過公開合法渠道獲得，如涉及侵權(quán)，請聯(lián)系我們刪除；如對報告內(nèi)容存疑，請與撰寫、發(fā)布機(jī)構(gòu)聯(lián)系